| APOGENIX GmbH Patent applications |
| Patent application number | Title | Published |
|---|
| 20110171212 | METHODS AND COMPOSITIONS FOR PREVENTING RADIATION-INDUCED PNEUMONITIS - Disclosed are methods of minimizing the risk for a patient of developing pneumonitis during radiotherapy for a thorax-associated neoplasm and compositions for use in such methods. A preferred composition comprises a CD95/CD95L inhibitor. Further disclosed is a method of increasing the radiation dose administered to a patient during radiotherapy for a thorax-associated neoplasm. | 07-14-2011 |
| 20110027218 | TNF SUPERFAMILY FUSION PROTEINS - The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications. | 02-03-2011 |
| 20100297110 | ANTIBODY SPECIFIC FOR HUMAN IL-4 FOR THE TREATMENT OF CANCER - The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer. | 11-25-2010 |
| 20100111969 | IL-4 RECEPTOR AND IL-13 AS PROGNOSTIC MARKERS FOR COLON AND PANCREAS TUMORS - The present invention relates to the use of IL-4 receptor and IL-13 expression as diagnostic and/or prognostic markers for tumors, such as colon and pancreas tumors. | 05-06-2010 |
| 20100086515 | HUMAN IL-4 MUTEINS IN CANCER THERAPY - The present invention relates to the use of a combination of human interleukin-4 muteins and chemotherapeutic or pro-apoptotic agents for the prevention and/or treatment of cancer disease. | 04-08-2010 |
| 20090196868 | METHODS AND COMPOSITIONS FOR PREVENTING RADIATION-INDUCED PNEUMONITIS - Disclosed are methods of minimizing the risk for a patient of developing pneumonitis during radiotherapy for a thorax-associated neoplasm and compositions for use in such methods. A preferred composition comprises a CD95/CD95L inhibitor. Further disclosed is a method of increasing the radiation dose administered to a patient during radiotherapy for a thorax-associated neoplasm. | 08-06-2009 |
